NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...
MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...
England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...
Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...
Dr Pavan Bhargava recently returned from the 2025 AAN Annual Meeting, where key updates in relapsing-remitting multiple sclerosis (RRMS) were highlighted. He noted the introduction of the 2024 ...
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in ...
Verywell Health on MSN
How multiple sclerosis is treated
Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple ...
Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...
- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis - - The ...
A new cellular balance test can detect a hidden inflammation in the brain, helping physicians to spot multiple sclerosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback